Health TrialsbyHealthPanel

Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer

ConditionsPancreas CancerPancreas NeoplasmPancreas DiseasePancreas AdenocarcinomaSurgeryChemotherapy EffectQuality of LifeLocally Advanced Pancreatic AdenocarcinomaBorderline Resectable Pancreatic Adenocarcinoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUmeå University

About this trial

This study aims to assess overall survival, quality of life and resection rates in locally advanced pancreatic cancer

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Confirmed or suspected invasive pancreatic primary tumor

Tumor classified as borderline resectable or locally advanced disease according to NCCN guidelines

Disqualifiers

Suspected endocrine tumor

Suspected non-pancreatic periampullary tumor

Distant metastasis

Age < 18 years

Trial population

Patients with a confirmed or suspected non-endocrine invasive pancreatic primary tumor that is classified as borderline resectable or locally advanced disease

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Median Overall Survival

Median overall survival for patients with locally advanced pancreatic cancer stratified for treatment allocation

Time frame
From date of inclusion until the date of death from any cause, assessed up to 72 months
2

Resection

Rates of resection among patients with locally advanced pancreatic cancer stratified for treatment allocation

Time frame
From the time of inclusion to end of study follow up or date of death from any cause, whichever came first, up to 72 months

Secondary outcomes

1

Oncological treatment compliance

Number of patients that complete a started oncological treatment and are able to complete regimen

Time frame
From the time of inclusion to end of study follow up or date of death from any cause, whichever came first, up to 72 months
2

Chemotherapy response

Percentage within each RECIST strata

Time frame
From the time of inclusion to end of study follow up or date of death from any cause, whichever came first, up to 72 months
3

Predictors of resectability

Logistic regression models assessing predictors of resectability

Time frame
From the time of inclusion to end of study follow up or date of death from any cause, whichever came first, up to 72 months
4

Quality of Life at baseline

Quality of life assessed with EORTC QLQ C30 focused on self-reported Global Health Score ranging from 1 to 7 where a higher number indicates better self-experienced health

Time frame
At first visit/inclusion

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Umeå University

Lead sponsor

University Hospital, Linkoeping

Collaborator

Lund University Hospital

Collaborator

Sahlgrenska University Hospital

Collaborator

Karolinska University Hospital

Collaborator

University Hospital, Umeå

Collaborator

Source ClinicalTrials.gov
Apply now